Product Description
Metoprolol is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks or strokes. These problems may be less likely to occur if blood pressure is controlled. (Sourced from: https://www.mayoclinic.org/drugs-supplements/metoprolol-oral-route/description/drg-20071141#:~:text=Metoprolol%20is%20used%20alone%20or,arteries%20may%20not%20function%20properly.)
Mechanisms of Action: ADRB1 Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Norway, Singapore, Spain
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lung Injury|Acute Respiratory Distress Syndrome|Cardiac Arrest|Cardiac Arrhythmias|Mitral Valve Prolapse|Respiratory Distress Syndrome, Newborn
Phase 2: Autism Spectrum Disorder
Phase 1: Erectile Dysfunction|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20242190 |
CTR20242190 | P1 |
Completed |
Erectile Dysfunction |
2024-11-15 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ACTRN12621000760875p |
2006-7041-83/hah | P2 |
Not yet recruiting |
Autism Spectrum Disorder |
2021-07-16 |
|||
NCT05631730 |
FLECAPRO | P3 |
Recruiting |
Mitral Valve Prolapse|Cardiac Arrest|Cardiac Arrhythmias |
2026-06-01 |
2025-07-31 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT05847517 |
MAIDEN | P3 |
Recruiting |
Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury |
2025-09-01 |
2024-09-20 |
||
NCT06808802 |
J1I-MC-GZQE | P1 |
Completed |
Healthy Volunteers |
2025-04-15 |
88% |
2025-08-27 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/12/2026 |
News Article |
CorMedix to Participate in Upcoming Investor Conferences |
|
02/02/2026 |
News Article |
CorMedix Therapeutics Announces Share Repurchase Program |
|
01/29/2026 |
News Article |
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 |
|
01/09/2026 |
News Article |
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |